|
|
| Ixabepilone
|
| Systematic (IUPAC) name
|
(1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-1,5,7,
9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol-
4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0]
heptadecane-8,12-dione
|
| Identifiers
|
| CAS number
| 219989-84-1
|
| ATC code
| L01DC04
|
| PubChem
| 6445540
|
| Chemical data
|
| Formula | C27H42N2O5S
|
| Mol. mass | 506.698 g/mol
|
| SMILES
| search in eMolecules, PubChem
|
| Synonyms
| Azaepothilone B
|
| Pharmacokinetic data
|
| Bioavailability | N/A
|
| Protein binding
| 67 to 77%
|
| Metabolism | Extensive, hepatic, CYP3A4-mediated
|
| Half life | 52 hours
|
| Excretion | Fecal (mostly) and renal
|
| Therapeutic considerations
|
| Pregnancy cat.
|
D(US)
|
| Legal status
|
℞-only(US)
|
| Routes
| Intravenous infusion
|
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.
Additional recommended knowledge
On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. ([1]). Ixabepilone is administered through injection, and will be marketed under the trade name
Ixempra.
| Chemotherapeutic agents/Antineoplastic agents (L01) |
|---|
| Alkylating and alkylating-like agents | Nitrogen mustards: (Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan). Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin). Platinum (alkylating-like): (Carboplatin, Cisplatin, Oxaliplatin, BBR3464). Busulfan, Dacarbazine, Procarbazine, Temozolomide, ThioTEPA, Uramustine |
|---|
| Antimetabolites | Folic acid: (Aminopterin, Methotrexate, Pemetrexed, Raltitrexed). Purine:(Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine). Pyrimidine:(Capecitabine, Cytarabine, Fluorouracil, Floxuridine, Gemcitabine) |
|---|
| Spindle poison/mitotic inhibitor | Taxane: (Docetaxel, Paclitaxel). Vinca: (Vinblastine, Vincristine, Vindesine, Vinorelbine). |
|---|
| Cytotoxic/antitumor antibiotics | Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Valrubicin) - streptomyces (Actinomycin, Bleomycin, Mitomycin, Plicamycin) - Hydroxyurea |
|---|
| Topoisomerase inhibitors | Camptotheca: (Camptothecin, Topotecan, Irinotecan), Podophyllum:(Etoposide, Teniposide) |
|---|
| CI monoclonal antibodies | Receptor tyrosine kinase (Cetuximab, Panitumumab, Trastuzumab) - CD20 (Rituximab, Tositumomab) - other (Alemtuzumab, Bevacizumab, Gemtuzumab) |
|---|
| Photosensitizers | Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin |
|---|
| Tyrosine kinase inhibitors | Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Sorafenib, Sunitinib |
|---|
| Other | retinoids (Alitretinoin, Tretinoin) - Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase (Pegaspargase), Bexarotene, Bortezomib, Denileukin diftitox, Estramustine, Ixabepilone, Masoprocol, Mitotane |
|---|
|
